Medicine and Dentistry
Neoplasm
83%
Prostate Cancer
68%
Transitional Cell Carcinoma
50%
Partial Nephrectomy
45%
Bladder Cancer
45%
Transurethral Resection
42%
Recurrent Disease
35%
Alanine Aminotransferase
34%
Bladder
31%
Mycobacterium Bovis BCG
30%
Bladder Tumor
26%
Radiation Therapy
26%
Invasive Bladder Cancer
26%
Prostate Specific Antigen
26%
Sarcopenia
26%
Cystectomy
25%
Frailty
25%
Hypofractionated Radiotherapy
22%
Nephron Sparing Surgery
22%
Biochemical Recurrence
22%
Fibronectin
22%
Urinary System
22%
Overall Survival
20%
Symptom
19%
Cystoscopy
19%
Urine Cytology
19%
Muscle Invasive Bladder Cancer
19%
Surgical Technique
17%
Radical Nephrectomy
17%
Surgery
16%
Tumor Recurrence
15%
Renal Artery
14%
Clinical Trial
14%
Kidney Tumour
14%
Surgical Margin
13%
Biopsy
13%
Bacilli
13%
Bleeding
13%
Kidney Function
13%
Seminal Vesicle
12%
Hematuria
12%
Pseudoaneurysm
12%
Prostatectomy
12%
Cohort Analysis
12%
Systematic Review
11%
Tumor Infiltrating Lymphocyte
11%
Urethral Catheterization
11%
Non Muscle Invasive Bladder Cancer
11%
Urologist
11%
Volumetric Modulated Arc Therapy
11%
Keyphrases
Prostate Cancer
47%
Laparoscopic Partial Nephrectomy
45%
Bladder Cancer
45%
Tumor
38%
Cancer Patients
36%
Prostate-specific Antigen
35%
Alanine Aminotransferase
34%
Sarcopenia
28%
Gemcitabine
28%
Upper Tract Urothelial Carcinoma
28%
Frailty
27%
Retrospective Analysis
26%
Prostate Cancer Patients
24%
Cystoscopy
23%
Nephron-sparing Surgery
22%
Biochemical Failure
22%
Hypofractionated Radiation Therapy
22%
Bacillus Calmette-Guérin
22%
Human Prostate
22%
Muscle-invasive Bladder Cancer
18%
Radical Nephrectomy
18%
Surgical Technique
17%
Transurethral Resection of Bladder Tumor (TURBT)
17%
Cancer Inpatients
17%
Treatment Outcome
17%
Urine Cytology
17%
Invasive Bladder Cancer
17%
Overall Survival
17%
Bladder Transitional Cell Carcinoma
16%
Superficial Bladder Cancer
16%
Cancer Survivors
14%
After Surgery
14%
Local Recurrence
14%
Renal Cancer
14%
Hematuria
14%
Renal Tumor
14%
Effective Treatment
14%
Partial Nephrectomy
14%
Prostate-specific Antigen Level
13%
Genitourinary Toxicity
13%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
13%
Bladder Tumor
13%
Retrospective Review
13%
Single-center Experience
13%
Laparoscopic Approach
13%
Intravesical Gemcitabine
13%
Bacillus Calmette
12%
Recurrent Tumor
12%
Renal Cell Carcinoma
12%
Local Control
12%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Prostate Specific Antigen
41%
Gemcitabine
30%
Androgen
25%
Biochemical Recurrence
25%
Fibronectin
22%
Mycobacterium Bovis BCG
22%
Prostate Tumor
22%
Docetaxel
22%
Estramustine Phosphate
22%
Chemotherapy
21%
Transitional Cell Carcinoma
20%
Bladder Cancer
18%
Recurrent Disease
16%
Neoplasm
14%
Bladder Tumor
12%
Bicalutamide
11%
Prostate Hypertrophy
11%
Sarcopenia
11%
Hyperthermia
11%
Disease Exacerbation
11%
Bisphosphonic Acid Derivative
11%
Non Muscle Invasive Bladder Cancer
11%
Tamsulosin
11%
Pharmacokinetics
11%
Castration Resistant Prostate Cancer
11%
Alanine Aminotransferase
11%
Mitomycin
11%
Anticarcinogen
11%
Alpha Adrenergic Receptor Blocking Agent
11%
Paclitaxel
11%
Marimastat
11%
Melatonin Receptor
11%
Lanoteplase
11%
Frailty
11%
Izonsteride
11%
Alfuzosin
11%
Melatonin
11%
Prostate Carcinoma
11%
Neuropathy
11%
Antiandrogen
9%
Tree
7%
Osteopenia
7%
Side Effect
6%
Thromboembolism
5%
Neutropenia
5%
Progression Free Survival
5%
Prostate Specific Membrane Antigen
5%
Hormone Cancer Therapy
5%
Androstenediol
5%